Efficacies of liposome-encapsulated streptomycin and ciprofloxacin against Mycobacterium avium-M. intracellulare complex infections in human peripheral blood monocyte/macrophages
Open Access
- 1 December 1992
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 36 (12) , 2808-2815
- https://doi.org/10.1128/aac.36.12.2808
Abstract
Current treatments of disseminated infection caused by the Mycobacterium avium-M. intracellulare complex (MAC) are generally ineffective. Liposome-mediated delivery of antibiotics to MAC-infected tissues in vivo can enhance the efficacy of the drugs (N. Düzgüneş, V. K. Perumal, L. Kesavalu, J. A. Goldstein, R. J. Debs, and P. R. J. Gangadharam, Antimicrob. Agents Chemother. 32:1404-1411, 1988; N. Düzgüneş, D. A. Ashtekar, D. L. Flasher, N. Ghori, R. J. Debs, D. S. Friend, and P. R. J. Gangadharam, J. Infect. Dis. 164:143-151, 1991). We investigated the therapeutic efficacies of liposome-encapsulated streptomycin and ciprofloxacin against growth of the MAC inside human peripheral blood monocyte/macrophages. Treatment was initiated 24 h after infection of macrophages with the MAC and stopped after 20 h, and the cells were incubated for another 7 days. The antimycobacterial activity of streptomycin was enhanced when the drug was delivered to macrophages in liposome-encapsulated form, reducing the CFU about threefold more than the free drug did throughout the concentration range studied (10 to 50 micrograms/ml). With 50 micrograms of encapsulated streptomycin per ml, the CFU were reduced to 11% of the initial level of infection. Liposome-encapsulated ciprofloxacin was at least 50 times more effective against the intracellular bacteria than was the free drug: at a concentration of 0.1 microgram/ml, liposome-encapsulated ciprofloxacin had greater antimycobacterial activity than the free drug at 5 microgram/ml. With liposome-encapsulated ciprofloxacin at 5 micrograms/ml, the CFU were reduced by more than 1,000-fold at the end of the 7-day incubation period, compared with untreated controls. These results suggest that liposome-encapsulated ciprofloxacin or other fluoroquinolones may be effective against MAC infections in vivo. ImagesKeywords
This publication has 30 references indexed in Scilit:
- Activity of free and liposome encapsulated streptomycin against Mycobacterium avium complex (MAC) inside peritoneal macrophagesJournal of Antimicrobial Chemotherapy, 1991
- Chemotherapeutic potential of free and liposome encapsulated streptomycin against experimental Mycobacterium avium complex infections in beige miceJournal of Antimicrobial Chemotherapy, 1991
- Treatment of Mycobacterium avium-intracellulare Complex Infection in Beige Mice with Free and Liposome-Encapsulated Streptomycin: Role of Liposome Type and Duration of TreatmentThe Journal of Infectious Diseases, 1991
- Mycobacterium aviumComplex Infection in the Acquired Immunodeficiency SyndromeNew England Journal of Medicine, 1991
- Treatment of Disseminated Mycobacterium avium Complex Infection of Beige Mice with Liposome-Encapsulated AminoglycosidesThe Journal of Infectious Diseases, 1990
- Synergistic effects of antimycobacterial drag combinations onMycobacterium avium complex determined radiometrically in liquid mediumEuropean Journal of Clinical Microbiology & Infectious Diseases, 1987
- Mycobacterial Infections in. AIDS Patients, with an Emphasis on the Mycobacterium avium ComplexClinical Infectious Diseases, 1986
- Interaction of liposomes with Kupffer cells in vitroExperimental Cell Research, 1984
- Preparation of unilamellar liposomes of intermediate size (0.1–0.2 μm) by a combination of reverse phase evaporation and extrusion through polycarbonate membranesBiochimica et Biophysica Acta (BBA) - Biomembranes, 1980
- The Glomerular Permeability Determined by Dextran Clearance Using Sephadex Gel FiltrationScandinavian Journal of Clinical and Laboratory Investigation, 1968